Melanoma and immunotherapy.
About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.
Eggermont
Alexander M M
AM
Department of Surgical Oncology, Erasmus University MC-Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands. a.eggermont@erasmusmc.nl
Schadendorf
Dirk
D
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D016207:Cytokines / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D015316:Genetic Therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D016233:Immunotherapy, Active; D016219:Immunotherapy, Adoptive; D008212:Lymphocyte Depletion; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012878:Skin Neoplasms / Q000628:therapy; D016019:Survival Analysis
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D016207:Cytokines; D007155:Immunologic Factors